(Q36496107)

English

A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Carruthers

4

object named as

David Carruthers

0 references

author name string

Paresh Jobanputra

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Fiona Maggs

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Alison Deeming

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

David Carruthers

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Elizabeth Rankin

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Alison C Jordan

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Abdul Faizal

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Carolyn Goddard

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Mark Pugh

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Simon J Bowman

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sue Brailsford

11

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Peter Nightingale

12

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

12 November 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Sustained rheumatoid arthritis remission is uncommon in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

A clinician's critique of rheumatoid arthritis health economic models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Barriers to participation in randomised controlled trials: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

30 September 2017

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532970

28 June 2018

It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues

1 reference

https://pubmed.ncbi.nlm.nih.gov/23148339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23148339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An audit of methotrexate and folic acid for rheumatoid arthritis. Experience from a teaching centre

1 reference

https://pubmed.ncbi.nlm.nih.gov/23148339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23148339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010

1 reference

https://pubmed.ncbi.nlm.nih.gov/23148339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJOPEN-2012-001395

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36496107&oldid=1746526390"